Relevant bibliographies by topics / Adjuvant therapies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Adjuvant therapies'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adjuvant therapies"

1

Castiglione, M. "63 Tailored adjuvant therapies." European Journal of Cancer Supplements 1, no. 5 (September 2003): S24. http://dx.doi.org/10.1016/s1359-6349(03)90098-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Seya, Tsukasa, Takashi Akazawa, Tadayuki Tsujita, and Misako Matsumoto. "Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies." Evidence-Based Complementary and Alternative Medicine 3, no. 1 (2006): 31–38. http://dx.doi.org/10.1093/ecam/nek010.

Full text
Abstract:
Effective therapeutic vaccines contain two primary constituents, antigen and adjuvant. Adjuvants consisting of microbial pattern molecules play a central role in vaccination. Successful vaccine requires efficient induction of antibody (Ab), type I interferons (IFN), cytokines/chemokines, cytotoxic T lymphocytes (CTL) and/or NK cells. Toll-like receptors (TLRs) in myeloid dendritic cells (mDC) essentially act as adjuvant receptors and sustain the molecular basis of adjuvant activity. Current consensus is that TLRs and their adapters introduce signals to preferentially induce IFN-α/β, chemokines and proinflammatory cytokines, and mature mDC to augment antigen presentation. Although most of these data were obtained with mice, the results are presumed to be adaptable to humans. Whenever TLR pathway is activated in mDC, NK and/or CTL activation is promoted. For induction of antigen-specific CTL toward phagocytosed material, cross-priming must be induced in mDC, which is also sustained by TLR signaling in mDC. Since the TLR responses vary with different adjuvants, mDC functions are skewed depending on adjuvant-specific direction of mDC maturation. It appears that the directed maturation of mDC largely relies on selection of appropriate sets of TLRs and their adapter signaling pathways. Synthetic chimera molecules consisting of TLR agonists and target antigens are found to be effective in induction of CTL to eliminate target cellsin vivo. Here, we review the role of human TLRs and adapters in a variety of host immune responses. We will also describe the relevance of adjuvants in the manipulation of receptors and adapters in vaccine therapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Kosmider, Suzanne. "Adjuvant therapies for colorectal cancer." World Journal of Gastroenterology 13, no. 28 (2007): 3799. http://dx.doi.org/10.3748/wjg.v13.i28.3799.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Abdelhakeem, Ahmed, and Mariela Blum Murphy. "Adjuvant Therapies for Esophageal Cancer." Thoracic Surgery Clinics 32, no. 4 (November 2022): 457–65. http://dx.doi.org/10.1016/j.thorsurg.2022.06.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ponzio, Humberto Antônio. "Combined strategies and adjuvant therapies." Expert Review of Dermatology 1, no. 1 (February 2006): 177–80. http://dx.doi.org/10.1586/17469872.1.1.177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Carina, Valeria, Viviana Costa, Maria Sartori, Daniele Bellavia, Angela De Luca, Lavinia Raimondi, Milena Fini, and Gianluca Giavaresi. "Adjuvant Biophysical Therapies in Osteosarcoma." Cancers 11, no. 3 (March 12, 2019): 348. http://dx.doi.org/10.3390/cancers11030348.

Full text
Abstract:
Osteosarcoma (OS) is a primary bone sarcoma, manifesting as osteogenesis by malignant cells. Nowadays, patients’ quality of life has been improved, however continuing high rates of limb amputation, pulmonary metastasis and drug toxicity, remain unresolved issues. Thus, effective osteosarcoma therapies are still required. Recently, the potentialities of biophysical treatments in osteosarcoma have been evaluated and seem to offer a promising future, thanks in this field as they are less invasive. Several approaches have been investigated such as hyperthermia (HT), high intensity focused ultrasound (HIFU), low intensity pulsed ultrasound (LIPUS) and sono- and photodynamic therapies (SDT, PDT). This review aims to summarize in vitro and in vivo studies and clinical trials employing biophysical stimuli in osteosarcoma treatment. The findings underscore how the technological development of biophysical therapies might represent an adjuvant role and, in some cases, alternative role to the surgery, radio and chemotherapy treatment of OS. Among them, the most promising are HIFU and HT, which are already employed in OS patient treatment, while LIPUS/SDT and PDT seem to be particularly interesting for their low toxicity.
APA, Harvard, Vancouver, ISO, and other styles
7

Romero, Diana. "Avoiding overuse of adjuvant therapies." Nature Reviews Clinical Oncology 15, no. 8 (June 19, 2018): 469. http://dx.doi.org/10.1038/s41571-018-0054-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kronowitz, Steven J., and Geoffrey L. Robb. "Breast Reconstruction and Adjuvant Therapies." Seminars in Plastic Surgery 18, no. 2 (May 2004): 105–15. http://dx.doi.org/10.1055/s-2004-829045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Loh, Wenyin, and Mimi Tang. "Adjuvant Therapies in Food Immunotherapy." Immunology and Allergy Clinics of North America 38, no. 1 (February 2018): 89–101. http://dx.doi.org/10.1016/j.iac.2017.09.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Singhi, S. "Effective Adjuvant Therapies for Meningitis." International Journal of Infectious Diseases 14 (March 2010): e331-e332. http://dx.doi.org/10.1016/j.ijid.2010.02.2230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Adjuvant therapies"

1

Caissie, Amanda L. "Cyclooxygenase-2 and other targets of adjuvant therapies for uveal melanoma." Thesis, McGill University, 2005. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=85893.

Full text
Abstract:
Uveal melanoma has a high mortality rate, with approximately 45% of patients dying due to liver metastasis within 15 years of initial diagnosis and local treatment. As the eye lacks lymphatics, there is no staging of uveal melanoma according to lymph node metastasis. The search for new prognostic factors and therapeutic targets is therefore crucial to the advancement of uveal melanoma research. The expression of cyclooxygenase-2 (COX-2) has been investigated in human malignancies such as cutaneous melanoma. Immunohistochemical studies were therefore used to show that uveal melanomas do express COX-2 and that this expression is associated with various histopathological markers of poor prognosis. A novel sub-classification of mixed-cell-type tumours was devised, according to COX-2 expression.
The numerous studies of COX-2 expression in human malignancies have focused on COX-2 expression in tumour cells. This work shows COX-2 to be expressed in uveal melanoma tumour cells and tumour-associated macrophages (TAM), with a higher amount of COX-2 expression associated with a higher amount of TAM infiltration. These results may help explain the poor prognosis previously attributed to a high amount of TAM infiltration in uveal melanoma.
This thesis also investigated the co-expression of COX-2, insulin-like growth factor 1 receptor (IGF-IR) and phosphorylated-Akt (p-Akt). A recent paper had shown IGF-1R expression to be associated with a higher risk of uveat melanoma metastasis. IGF-1R expression, present to different degrees in almost all uveal melanoma cases, represents the presence of the receptor, whereas p-Akt expression represents an activated downstream pathway. This thesis showed that p-Akt is expressed in uveal melanoma. While some uveal melanoma cases co-expressed COX-2, IGF-1R and p-Akt, all cases were positive for at least one of the three markers.
Studies in human malignancies, including uveal melanoma, have shown COX-2 inhibitors to have effects on both COX-2 positive and negative tumour cells. The effects of COX-2 inhibitors on IGF-1R and p-Akt have been postulated as possible mechanisms behind these COX-2 independent effects. This work has provided a rationale for the study of COX-2 inhibitors, alone or in combination with IGF-1R inhibitors, as systemic adjuvant treatment of this life-threatening intra-ocular malignancy.
APA, Harvard, Vancouver, ISO, and other styles
2

Patil, Pradeep. "Développement de thérapies adjuvantes associées à l’anti-cytoadhérence." Thesis, Montpellier 2, 2011. http://www.theses.fr/2011MON20172/document.

Full text
Abstract:
Titre de la thèse : Développement de thérapies adjuvantes associées à l'anti-cytoadhérence. Résumé : L'antigène de surface PfEMP-1 (P. falciparum Erythrocyte Membrane Protein-1) encodé par 60 gènes de la famille var du parasite, est un facteur de virulence du paludisme touchant l'Homme. Les différents variants de PfEMP-1 sont impliqués dans la cytoadhérence des érythrocytes infectés par P. falciparum (iRBCs) avec plusieurs récepteurs de l'endothélium vasculaire de l'hôte. Parmi eux, l'interaction avec ICAM-1 semble être liée à des manifestations sévères de la maladie telles que le paludisme cérébral. La majorité de la mortalité due à un paludisme sévère est observée dans les 24 heures après admission à l'hôpital, malgré l'utilisation d'antipaludiques efficaces, soulignant ainsi un besoin urgent en thérapies adjuvantes ciblant spécifiquement la cytoadhérence.Le site d'interaction d'ICAM-1 avec les érythrocytes infectés a été identifié au niveau du « BED side » de son domaine N-terminal, similaire à celui des immunoglobulines. Les variants antigéniques de P. falciparum capables de se lier à ICAM-1 présentent des différences subtiles au niveau des résidus responsables de cette interaction. La boucle DE semble être l'élément commun des sites de fixation à ICAM-1 pour trois variants de P. falciparum (ITO4-A4, ITO4-C24 and ItG-ICAM) et fut ainsi choisie par le groupe de Matthias Dormeyer comme cible pour un criblage in silico. Une librairie de structures de petites molécules fut criblée en utilisant une technique d'alignement moléculaire fournie par le programme 4Scan. Grâce à cette étude, la molécule (+)-epigalloyl-cathechin-gallate (EGCG) fut identifiée comme un inhibiteur d'interaction très spécifique et dose-dépendant pour deux des trois variants.Notre projet fut de développer des composés anti-adhésifs capables d'inhiber ou de supprimer l'interaction des hématies infectées avec les récepteurs endothéliaux. Tout d'abord, nous avons réalisé une série de substitues tetrahydroisoquinolines, analogues au composé naturel EGCG précédemment découvert. Ensuite, nous avons basé notre recherche sur la synthèse de composés peptidiques simulant des régions spécifiques d'ICAM-1 qui peuvent être impliquées dans l'interaction avec les variants de PfEMP1. Le design de ces peptides a été dirigé par le groupe du Prof. Tramontano sur la base d'analyses in silico de l'interaction moléculaire entre ICAM-1 (dont la structure cristallographique est connue) et un modèle de PfEMP1. Nous avons étudié les propriétés d'inhibition de la cytoadhérence de plusieurs de ces peptides afin de créer une base pour le design de molécules peptidomimétiques dotées de meilleures propriétés médicamenteuses.Finalement, afin d'élargir notre étude, EGCG a été criblé contre un panel de nouveaux isolats de P. falciparum provenant de patients et capables d'interagir avec ICAM-1. Ses propriétés anti-adhésives ont été étudiées afin de connaitre l'impact des variations de ces souches sur l'interaction et pour guider le design d'un inhibiteur de cytoadhérence à large spectre.INTITULÉ ET ADRESSE DE L'U.F.R. OU DU LABORATOIRE : - Prof. Giuseppe Campiani - Università degli Studi di Siena - Dipt. Farmaco-Chimico Tecnologico. Via Aldo Moro, 2, 53100, Siena (Italy) - Prof. Alister Craig – Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3, 5QA, UK
Thesis title-: Development of anti-cytoadherence adjunct therapies.Thesis abstract-Parasite derived surface antigen PfEMP-1 (P. falciparum erythrocyte membrane protein-1) encoded by 60 var genes, is a virulence factor of the human malaria parasite. PfEMP-1 variants have been implicated in the cytoadherence of P. falciparum infected erythrocytes (iRBCs) to several binding receptors on host vascular endothelium. Among them, binding to ICAM-1 seems to be related to severe manifestations of the disease such as cerebral malaria. The majority of the mortality with severe malaria is seen within 24 hours of hospital admission despite the use of effective anti-parasite drugs, therefore the development of adjunctive therapies specifically targeting cytoadherence is urgently needed.The binding site for iRBC has been mapped to the BED side of the N-terminal immunoglobulin-like domain of ICAM-1, and shows subtle differences in the contact residues used by ICAM-1 binding P. falciparum antigenic variants. The DE loop appears to be a common feature of the ICAM-1 binding sites for three P. falciparum variants (ITO4-A4, ITO4-C24 and ItG-ICAM) analyzed and was selected by Matthias Dormeyer group for in silico screening of a small-molecule structures library using a molecular-alignment technique based on the program package 4Scan. From this study, (+)-epigalloyl-cathechin-gallate (EGCG) was found to inhibit binding of two variant ICAM-1 binding parasites in a highly specific, dose-dependent manner.Our approach to this need has been the development of anti-adhesive compounds to inhibit and reverse the binding of iRBCs to endothelial receptors. Firstly, we developed a series of substituted tetrahydroisoquinolines as analogues of the natural compound EGCG previously identified. Secondly, we based our research on the synthesis of peptidic compounds mimicking specific ICAM-1 regions hypothesized to be involved in the binding with disease-relevant PfEMP1 variants. The design of the peptides has been conducted by the group of Prof. Tramontano on the basis of an in silico analysis of the molecular interaction between ICAM-1 (whose crystal structure is known) and a homology model of PfEMP1. We have evaluated several peptides for their cytoadherence blocking properties and the results of this studies could form the basis for the design of peptidomimetics endowed with better drug-like properties. Finally, to extend previous studies, EGCG has been screened against a panel of new ICAM-1 binding patient isolates of P. falciparum for its anti-adhesive properties to investigate the impact of iRBC strain variation and to guide the design of a broad-spectrum cytoadherence inhibitor.TITLE AND ADDRESS OF LABORATOIRE : Prof. Giuseppe Campiani - Università degli Studi di Siena - Dipt. Farmaco-Chimico Tecnologico. Via Aldo Moro, 2, 53100, Siena, Italy. Prof. Alister Craig – Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3, 5QA, UK
APA, Harvard, Vancouver, ISO, and other styles
3

Salazar, Marcela d'Alincourt. "Genomic Effects of Hormonal Adjuvant Therapies that Could Support the Emergence of Drug Resistance in Breast Cancer." University of Toledo Health Science Campus / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=mco1280929084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Niesel, Katja Anne [Verfasser], Beatrix [Akademischer Betreuer] Süß, and Ralf [Akademischer Betreuer] Galuske. "The influence of radio-immunotherapy on the tumor microenvironment of breast-to-brain metastasis and the investigation of novel adjuvant therapies / Katja Anne Niesel ; Beatrix Süß, Ralf Galuske." Darmstadt : Universitäts- und Landesbibliothek, 2021. http://d-nb.info/1234150018/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rozenfeld, Julio Henrique Kravcuks. "Arranjos supramoleculares de oligodeoxinucleotídeos e fragmentos de bicamada catiônica: preparação, caracterização e atividade imunoadjuvante." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/46/46131/tde-25042011-135215/.

Full text
Abstract:
A interação entre fragmentos de bicamada (BF) de brometo de dioctadecildimetilamônio (DODAB) e um mononucleotídeo-modelo (deoxiadenosina monofosfato, dAMP) ou um oligodeoxinucleotídeo-modelo (5\'- AAAAAAAAAA-3\', poli(dA)) ou um oligodeoxinucleotídeo terapêutico (5\'- TTGACGTTCG -3\', CpG) foi investigada por turbidimetria, espalhamento de luz dinâmico, espectroscopia de dicroísmo circular e de fluorescência e calorimetria diferencial de varredura (DSC). Respostas imunológicas foram caracterizadas com ensaio de hipersensibilidade tardia por inchamento de coxim patelar de camundongo, dosagem de anticorpos IgG1 e IgG2a e de citocinas secretadas por células de linfonodo em cultura. Poli(dA), em contraste com dAMP, induziu fusão máxima de DODAB BF a partir da neutralização de cargas, quando houve obtenção de um tamanho máximo e um potencial-zeta igual a zero para os arranjos. Para [poli(dA)] maiores do que aquela correspondente à neutralização de cargas, houve recuperação da estabilidade coloidal com reversão do potencial-zeta e com obtenção de tamanhos que foram aproximadamente o dobro daqueles determinados inicialmente para DODAB BF. A proporção molar de neutralização poli(dA): DODAB foi 1:10 para DODAB BF e 1:20 para vesículas grandes (LV) de DODAB, de acordo com as estruturas de bicamada aberta e fechada dessas duas dispersões de bicamada de DODAB. A fusão de DODAB BF induzida por poli(dA) foi extensiva aumentando o grau de empacotamento das bicamadas formadas conforme inferido a partir dos termogramas de DSC. Em condições de equivalencia de cargas, nucleotídeo não causou fusão de DODAB BF, mostrando a importância do caráter de polieletrólito do poli(dA) para induzir fusão. O sal divalente Na2HPO4 causou fusão e aumentou o empacotamento da bicamada graças à blindagem eficiente de cargas. Reestabilização coloidal como aquela induzida por poli(dA) não ocorreu em presença de Na2HPO4, NaCl ou nucleotídeo. Para complexos DODAB BF/CpG em presença de ovalbumina (OVA) como antígenomodelo, a neutralização de cargas de DODAB BF/OVA por CpG reduziu a estabilidade coloidal, enquanto que supercompensação de cargas levou à reestabilização por repulsão eletrostática, como observado para a interação DODAB BF/poli(dA). Diferenças no tamanho e nas proporções de neutralização por CpG indicaram que os fragmentos são capazes de carregar mais moléculas de OVA do que de BSA. Na região de supercompensação de cargas com potenciais-zeta negativos, arranjos Al(OH)3/ OVA/ CpG são coloidalmente bem mais instáveis que DODAB BF/ OVA ou DODAB BF / OVA/ CpG. O complexo negativamente carregado DODAB (0,1 mM) / OVA (0,1mg/mL)/ CpG (0,020 mM) potencializou a resposta Th1 obtida com DODAB (0,1 mM)/ OVA (0,1 mg/mL). Houve um aumento de 25 % no inchamento do coxim patelar, de 36 % na produção de IFN-γ, de 60 % de IL-12 e produção sustentada de IgG2a ao longo de 35 dias pós-imunização, todos indícios fortes de potencialização da resposta Th1 por CpG. Arranjos negativamente carregados de oligonucleotídeos em fragmentos de bicamada de DODAB possuem excelente potencial para terapias baseadas em oligonucleotídeos e para produção de vacinas para diferentes antígenos de interesse.
The interaction between bilayer fragments (BF) of dioctadecyldimethylammonium bromide (DODAB) and a model nucleotide (deoxyadenosine monophosphate, dAMP) or a model oligodeoxynucleotide (5\'- AAAAAAAAAA-3\', poly(dA)) or a therapeutic oligodeoxynucleotide (5\'- TTGACGTTCG -3\', CpG) was investigated by means of turbidimetry, dynamic light scattering, circular dichroism and fluorescence spectroscopies and differential scanning calorimetry. Immune responses were characterized using footpad swelling delayed type hipersensitivity assay and antibody and cytokine measurements. In contrast to dAMP, poly(dA) induced maximal DODAB BF fusion from charge neutralization, where assemblies presented maximal size and zero zeta-potential. Above charge neutralization colloid stability was recovered with negative zeta-potentials and sizes that were about the double of those initially determined for DODAB BF. The poly(dA):DODAB molar ratio for neutralization was 1:10 for DODAB BF and 1:20 for DODAB LV, in agreement with the open and closed bilayer structures of these two DODAB bilayer dispersions. The poly(dA)-induced DODAB BF fusion was extensive and increased the packing of the formed bilayers, as inferred from DSC thermograms. In conditions of charge equivalence, nucleotide did not cause DODAB BF fusion, highlighting the importance of poly(dA)\'s polyelectrolyte character to induce fusion. Divalent Na2HPO4 salt caused fusion and increased bilayer packing due to efficient BF charge shielding. Colloid restabilization as induced by poly(dA) was not observed in presence of Na2HPO4, NaCl and nucleotide. For DODAB BF/CpG complexes in presence of the ovalbumin (OVA) model antigen, the charge neutralization of DODAB BF/OVA by CpG reduced colloid stability, while charge overcompensation led to restabilization due to electrostatic repulsion, as observed for DODAB BF/poly(dA) interaction. Differences in size and neutralization proportions by CpG indicate that BF are able to load more OVA than BSA molecules. In the charge overcompensation region with negative zeta-potentials, Al(OH)3/OVA/CpG assemblies are colloidally less stable than DODAB BF/OVA or DODAB BF/OVA/CpG. The negatively charged DODAB (0.1mM)/OVA (0.1mg/ml)/CpG (0.020mM) assembly enhanced the Th1 response obtained with DODAB (0.1mM)/OVA (0.1mg/ml). There was a 25% increase in footpad sweeling, a 36% and 60% increase in the production of IFN-γ and IL-12 and sustained IgG2a production for the 35-day period after immunization, all indicative of strong Th1 response enhancement by CpG. Negatively charged assemblies of oligonucleotides in DODAB bilayer fragments have excellent potential in oligonucleotidebased therapies and in vaccine production for different antigens of interest.
APA, Harvard, Vancouver, ISO, and other styles
6

Hsieh, Jeff Ching-Fu. "Bayesian statistical models for understanding health-related outcomes for women screened for breast cancer." Thesis, Queensland University of Technology, 2016. https://eprints.qut.edu.au/100033/1/Jeff%20Ching-Fu_Hsieh_Thesis.pdf.

Full text
Abstract:
This thesis aims to understand the effects of women's residential location on breast cancer outcomes associated with screening, with a focus on women living in Queensland, Australia. It examines the spatial survival inequalities in health outcomes among these women by means of Bayesian spatial models and presents the inequalities with thematic maps across the state. The thesis investigated the spatial inequalities of various patient demographic, clinical and geographic factors as well as the intended use of cancer treatment among women with screen-diagnosed breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
7

Oettle, Helmut. "Entwicklung von neuen Behandlungskonzepten zur Therapie des Pankreaskarzinoms." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/13797.

Full text
Abstract:
Jährlich erkranken in Deutschland über 11.000 Patienten an Pankreaskarzinomen. Für die ganz überwiegende Mehrzahl dieser Patienten ist die Diagnosestellung gleichbedeutend mit einem Todesurteil innerhalb von wenigen Wochen, hauptsächlich bedingt durch das meist fortgeschrittene Krankheitsstadium bei Diagnosestellung sowie die relative Therapieresistenz des Tumors. Die vorliegende Arbeit faßt wissenschaftliche Untersuchungen zusammen, die in den zurückliegenden vier Jahren in Berlin zu dieser Thematik durchgeführt wurden. Stadienadaptiert wurden Behandlungskonzepte und klinische Studien entwickelt und durchgeführt, die von der adjuvanten Chemotherapie über ein Radiochemo-therapiekonzept bei lokal fortgeschrittenen Stadien hin zur Entwicklung einer neuen Zytostatika-Kombinationstherapie für die Behandlung metastasierter Pankreastumoren im Rahmen einer multinationalen Phase III Studie geführt haben. Neben diesen Schemata konnte auch eine wirksame Zweitlinientherapie geprüft werden. An Tumormaterial konnte gezeigt werden, daß sich keine Her2/neu-Überexpressionen bei Pankreastumoren nachweisen lassen, die therapeutisch nutzbar wären. Bei ca. 80 % aller Pankreaskarzinome lassen sich Mutationen des K-ras-Onkogens nachweisen. In Kooperation mit einer anderen Arbeitsgruppe wurde ein Verfahren entwickelt, mit dem sich qualitativ und semiquantitiativ schnell und zuverlässig ras-Mutationen nachweisen lassen. Diese klinischen Studienergebnisse geben Grund zur Hoffnung, die Prognose von Patienten mit Pankreaskarzinomen in den nächsten Jahren durch die hier vorgestellten Konzepte zu verbessern. Fortschritte im Verständnis der molekularen Karzinogenese, in Diagnostik und Therapie lassen in naher Zukunft Ergebnisse erwarten, die zumindest denen bei anderen soliden Tumoren nahekommen. Daher ist der vereinzelt noch verbreitete therapeutische Nihilismus bei der Behandlung des Pankreaskarzinoms als nicht länger gerechtfertigt und akzeptabel anzusehen.
In Germany, more than 11,000 patients are diagnosed with pancreatic cancer each year. For the vast majority, this means a death verdict within a few weeks, primarily due to the advanced stage of the disease at diagnosis and the relative chemoresistance of the tumor. This thesis summarizes the scientific work regarding pancreatic cancer that has been done within the last four years. Several clinical treatment concepts and studies were developed and conducted that covered the different stages of the disease, including adjuvant therapy, radiochemotherapy for locally advanced disease and a multinational phase III study for the patients with metastatic disease. In addition, an effective second line regimen was developed. Using tumor material, we found no overexpression of Her2/neu which would have been a therapeutically usable target. Mutations of the K-ras oncogene can be found in approximately 80% of patients with pancreas carcinoma. A method for a rapid and reliable qualitative and semiquantitative determination detection of ras mutations was developed in cooperation with another research group. The clinical results give rise to the hope that the prognosis of patients with pancreatic carcinoma can be improved during the next years using the concepts outlined above. Recent improvements in our understanding of the molecular carcinognesis together with advances in diagnostics and therapy give rise to the expectation that clinical results will be achievable that will be at least as good as those for other solid tumors. Therefore, nihilism regarding the treatment of pancreatic cancer that still can be found is no longer justifiable or acceptable.
APA, Harvard, Vancouver, ISO, and other styles
8

Hartmann, Claudia Helena. "Grundlagen für zielgerichtete adjuvante Therapien solider Tumore." Diss., lmu, 2006. http://nbn-resolving.de/urn:nbn:de:bvb:19-73460.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wirth, Manfred. "Delaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134720.

Full text
Abstract:
The advent of prostate-specific antigen (PSA) testing and increased patient awareness has led to patients being diagnosed with prostate cancer at an earlier stage and a younger age than previously. Adjuvant hormonal therapy to radiotherapy or prostatectomy has been shown to reduce the risk of tumour progression, and in some studies survival benefits have been demonstrated. The non-steroidal antiandrogen bicalutamide (‘Casodex’) has undergone extensive evaluation and is currently undergoing clinical trials as immediate therapy, either alone or as adjuvant to treatment of curative intent in patients with localized or locally advanced disease. Data from the first analysis of one of the studies in the Early Prostate Cancer (EPC) programme involving 3,603 patients have shown that, after a median follow-up of 2.6 years, the risk of prostate cancer progression was significantly reduced (by 43%) in patients receiving bicalutamide 150 mg compared with those receiving standard care alone (HR 0.57; 95% CI 0.48, 0.69; p ≪ 0.0001). The risk of PSA progression was also significantly reduced (by 63%). At this stage the survival data are still immature. Side effects of bicalutamide were mostly gynaecomastia and breast pain, which is consistent with its pharmacology. Overall withdrawal rates were similar in the bicalutamide 150 mg and standard care alone groups. In the bicalutamide 150 mg group, withdrawals were mainly due to side effects, whereas in the group receiving standard care alone, withdrawals were mainly due to disease progression. The programme is ongoing, and survival data are awaited
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
10

Lode, Holger N. "Strategien zur Immuntherapie beim Neuroblastom." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2003. http://dx.doi.org/10.18452/13902.

Full text
Abstract:
Das Neuroblastom ist ein vom sympathischen Nervensystem ausgehender neuroektodermaler maligner Tumor des Kleinkindesalters. Bei über 50% der Neuroblastom-Ersterkrankungen liegt bereits das disseminierte Stadium 4 vor, das eine infauste Prognose hat. Eine wirksame Behandlung des Stadium 4 Neuroblastoms stellt deshalb nach wie vor eine der größten Herausforderungen der pädiatrischen Onkologie dar: Die Gesamtüberlebensrate von 20-25% der Kinder, die an dieser bösartigen Krankheit leiden, konnte während der letzten zwei Jahrzehnte trotz neuer Chemotherapie-Protokolle nicht wesentlich verbessert werden. Aus diesem Grund gibt es zunehmend Bestrebungen sich um Therapiealternativen zu bemühen. In dieser Arbeit werden die derzeit möglichen immunologischen Strategien zur Behandlung des Neuroblastoms abgehandelt.
Neuroblastoma is a neuroectodermal malignancy of early childhood derived from sympathetic nervous tissue. At initial diagnosis over 50% of patients present with disseminated stage 4 disease which has a dismal prognosis. Effective treatment of patients with stage 4 neuroblastoma remains a major challenge in pediatric oncology. Despite novel therapeutic approaches including chemotherapy and autologous stem cell transplantation the overall survival rate of only 20-25% did not improve over the last two decades. Therefore, a lot of effort has been made to develop novel alternative therapies. This thesis summarizes possible immunotherapeutic strategies for the treatment of neuroblastoma.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Adjuvant therapies"

1

Group, The Philip Lief, ed. Depression: How to combine the best of traditional and alternative therapies. Avon, Mass: Adams Media Corp., 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Janelle, Wheat, and Currie Geoffrey, eds. Introduction to integrative oncology. Alexandria, N.S.W: Panaxea, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Springer, Wolfgang, and Christoph Abermann. Kombinierte Arzneimittel in der Homöopathie: 3 Tabellen. Stuttgart: Haug, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

A, Cynober Luc, ed. Metabolic and therapeutic aspects of amino acids in clinical nutrition. 2nd ed. Boca Raton: CRC Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mathé, G., and G. Bonadonna. Adjuvant Therapies of Cancer. Springer-Verlag, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bonadonna, Gianni, and Georges Mathé. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors. Brand: Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bonadonna, Gianni, G. Mathe, and S. E. Salmon. Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I: Markers and General Problems of Cancer Adjuvant Therapies. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.

Full text
Abstract:
Hormone therapy describes the role of hormones in the growth of a variety of cancers, and the therapeutic effects of manipulation of hormone levels in these diseases. Sex hormones stimulate the growth of breast and prostate cancers, many of which respond to surgical removal of the hormone-secreting gonad. Pharmacological measures to deliver hormone therapy in these diseases include luteinising hormone releasing hormone (LHRH) agonists and antagonists, inhibitors of sex hormone synthesis, and inhibitors of hormone-receptor binding. These treatments have established benefits in both in the control of advanced disease and the adjuvant therapy of early-stage disease. The pros and cons of combination hormone therapy are discussed. Resistance to hormone therapy may be primary or acquired, and the likely mechanisms are described.
APA, Harvard, Vancouver, ISO, and other styles
10

Jean Deslauriers MD FRCPS(C) CM, F. G. Pearson MD, and Farid M. Shamji MD FRCS ©. Lung Cancer, Part II: Surgery and Adjuvant Therapies, An Issue of Thoracic Surgery Clinics. Elsevier, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Adjuvant therapies"

1

Guglielmi, Alfredo, Andrea Ruzzenente, and Calogero Iacono. "Adjuvant and Neoadjuvant Therapies." In Surgical Treatment of Hilar and Intrahepatic Cholangiocarcinoma, 169–73. Milano: Springer Milan, 2007. http://dx.doi.org/10.1007/978-88-470-0729-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mang, Werner L. "Adjuvant Therapies, Including Laser Surgery." In Manual of Aesthetic Surgery 1, 225–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-662-08479-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mang, Werner L., Frank Neidel, Andrea Becker, Marian Stefan Mackowski, Jan-Thorsten Schantz, and Ulrike Then-Schlagau. "Adjuvant Therapies, Including Laser Surgery." In Manual of Aesthetic Surgery, 541–627. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-78795-2_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Palazzo, Antonella, and Marco Colleoni. "Adjuvant Systemic Therapies by Subtypes: Guidelines." In Breast Cancer, 535–39. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Prove, A., L. A. Teuwen, and L. Dirix. "Adjuvant Molecular Therapies in Breast Cancer." In Breast Cancer Management for Surgeons, 447–52. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56673-3_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ibrahim, Toni, and Federica Recine. "Bone-Targeted Therapies in Adjuvant Setting." In Management of Bone Metastases, 27–39. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-73485-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jones, Bleddyn, and Kirsten I. Hopkins. "13 Chemotherapy and other adjuvant therapies." In Radiobiological Modelling in Radiation Oncology, 234–45. 48–50 St John Street, London EC1M 4DG, UK: The British Institute of Radiology, 2007. http://dx.doi.org/10.1259/9780905749839.chapter13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rutkowski, Piotr. "Neoadjuvant and Adjuvant Therapies of Melanoma." In New Therapies in Advanced Cutaneous Malignancies, 401–15. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64009-5_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Selvi, Radhakrishna. "Adjuvant/Neoadjuvant Systemic Therapies in Breast Cancer." In Breast Diseases, 329–38. New Delhi: Springer India, 2014. http://dx.doi.org/10.1007/978-81-322-2077-0_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Harrington, Kevin J. "Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?" In Critical Issues in Head and Neck Oncology, 205–19. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_14.

Full text
Abstract:
AbstractDespite significant technical improvements in the management of patients with locoregionally-advanced head and neck cancers, too many patients fail to achieve durable remissions that ultimately translate into cures. Loco-regional recurrence and/or metastatic relapse after intensive local therapies remain the scourge of those who suffer from this disease, and the surgeons and physicians who treat them. Regrettably, until now, we have failed to develop effective adjuvant therapies that can be delivered after the completion of definitive loco-regional treatment in order to reduce the risk of disease relapse. In this chapter, approaches based on cytotoxic chemotherapy, targeted therapies directed against c-erbB/HER receptors and immune checkpoint inhibition will be discussed. Neither cytotoxic chemotherapy nor anti-HER-family targeted therapies have proven to be successful as adjuvant therapies for locoregionally-advanced head and neck cancers, but there is significant hope that anti-PD1/anti-PD-L1-targeted antibody therapies may deliver progress in this area for the first time.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adjuvant therapies"

1

Katsuta, E., and K. Takabe. "Abstract P4-06-12: Murine radical mastectomy model for preclinical study of adjuvant systemic therapies." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p4-06-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gandhi, C., EC Butler, S. Pesek, R. Kwait, M. Clark, C. Raker, A. Stuckey, and J. Gass. "Abstract P6-12-25: Sexual function in breast cancer survivors stratified by adjuvant therapies and surgical modalities." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p6-12-25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mullen, Matthew G., Timothy E. Newhook, James M. Lindberg, Sara J. Adair, Edik M. Blais, Alex D. Michaels, Edward B. Stelow, Jason A. Papin, J. Thomas Parsons, and Todd W. Bauer. "Abstract A47: A patient-derived xenograft model of pancreatic cancer in mice to develop novel adjuvant therapies." In Abstracts: AACR Special Conference on Tumor Metastasis; November 30-December 3, 2015; Austin, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tummet15-a47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yang, Deng-Fu, and Yih-Chih Hsu. "Combination therapies in adjuvant with topical ALA-mediated photodynamic therapy for DMBA-induced hamster buccal pouch premaligant lesions." In SPIE BiOS, edited by Wei R. Chen. SPIE, 2012. http://dx.doi.org/10.1117/12.907550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cha, Jong-Ho, Wen-Hao Yang, Weiya Xia, Yongkun Wei, Li-Chuan Chan, Seung-Oe Lim, Chia-Wei Li, et al. "Abstract A16: Metformin is a potential nontoxic adjuvant to enhance the efficacy of non-PDL1/PD-1 targeting immune therapies." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 27-30, 2018; Miami Beach, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm18-a16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Oliveira, Persis Araújo, Juliana Campelo Aragão Bitencourt, and Lorena Natali Cardoso Fernandes Caldas. "DIAGNOSTIC CHALLENGE OF A LOCALLY ADVANCED LESION: CASE REPORT OF PRIMARY BREAST ANGIOSARCOMA." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1082.

Full text
Abstract:
Introduction: Primary angiosarcoma of the breast (PAOB) is a class of extremely rare sarcomas, with an incidence rate of 1/2,000 cases of breast cancer worldwide. It is more frequent in 20- and 50-year-old women without history of previous cancer and commonly described in the left breast. Clinical presentation can be the same as usual breast cancer and histology can mimic poorly differentiated ductal carcinoma, which is why immunohistochemistry should be performed. Swelling, a feeling of fullness and exponential growth within the breast are frequent complaints, as noted by Kunkiel et al. in their series of case reports. The natural history of PAOB is only partly understood, suggesting that the lesion begins within the mammary parenchyma and then infiltrates skin and subcutaneous tissue nearby. The predominant management has been mastectomy, mainly, or sectorectomy with clear margins in cases of conservative breast surgery. Adjuvant therapies are not associated with improved survival, except for adjuvant chemotherapy in localized tumors of 5 cm or more. Case report: S.O.S., a 32-year-old woman, identified breast asymmetry in 2017, during the lactation period, presence of mild pain and swelling in the left breast. She was admitted to the breast cancer and benign lesions outpatient clinic at Professor Alberto Antunes University Hospital in February 2019. She held a BI-RADS 4 breast magnetic resonance imaging (MRI) in January 2019, which suggestedan irregular mass in the left breast, probably of vasculolymphatic nature; also showed core biopsy in February 2019: low-grade PAOB. In April 2019, she underwent a modified radical mastectomy of the left breast with ipsilateral lymphadenectomy. Due to the large extent of the lesion, an entire cutaneous area of left anterior hemithorax was resected, and thoracoepigastric flap was used to close the left hemithorax. An anatomopathological report diagnosed PAOB grade I. In July 2019, immunohistochemistry corroborated the diagnosis of PAOB with CD31 positive; positive von Willebrand factor (Factor VIII - polyclonal Rabbit) and ki67 positive for 25% of neoplastic cells. In the fourth month after the surgery, the patient started adjuvant radiotherapy, concluding it in October 2019. In post-treatment follow-up, in January 2021, she was referred to the breast reconstruction program, awaiting the procedure until this report was made.
APA, Harvard, Vancouver, ISO, and other styles
7

Arriaga, Yull, Joseph Tkacz, M. Christopher Roebuck, Judy George, Van Willis, and Irene Dankwa-mullan. "Abstract 2617: Factors associated with utilization of post-mastectomy adjuvant therapies in privately insured female patients with early-stage invasive breast cancer." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2617.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ochoa, O., S. Pisano, M. Chrysopoulo, P. Ledoux, G. Arishita, and C. Nastala. "Abstract P6-03-09: Internal mammary lymph node biopsy during free flap breast reconstruction: Accurate oncologic staging leads to change in adjuvant therapies." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p6-03-09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chan, A., C. Speers, S. O'Reilly, R. Pickering, S. Chia, and S. Chia. "Adherence of Adjuvant Hormonal Therapies in Post-Menopausal Hormone Receptor Positive (HR+) Early Stage Breast Cancer: A Population Based Study from British Columbia." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Francis, PA, GF Fleming, MM Regan, O. Pagani, BA Walley, KN Price, AS Coates, A. Goldhirsch, and R. Gelber. "Abstract OT3-02-03: Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-ot3-02-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Adjuvant therapies"

1

Fang, Shengyi, Piao Long, Yuying Yang, Dan Ouyang, and Jianzhong Cao. Clinical efficacy and safety of Traditional Chinese Medicine adjuvant Therapies for hepatitis B virus related Hepatocellular Carcinoma: A protocol for Network Meta-Analysis and Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Adjuvant therapies' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography